Biomarker for Infection Risk in CLL and MM

Eligibility Criteria

• * Adults ≥18 years of age.
• * Diagnosis of Rai stage I-IV chronic lymphocytic leukemia or small lymphocytic lymphoma or multiple myeloma.
• * Subjects must be able to consent to clinical trial, or documented health care proxy agent able to consent on behalf of participant.
• * Subjects must not have received IVIG administration within 6 calendar months of registration or have planned immunoglobulin replacement therapy by treating investigator at time of registration.
• * Subjects with chronic lymphocytic leukemia or small lymphocytic lymphoma must not be Rai stage 0.
• * Subjects with multiple myeloma must not have smoldering myeloma or solitary plasmacytoma with or without minimal marrow involvement.
• * Subjects must not have undergone prior autologous, allogeneic stem cell, or solid organ transplant.
• * Subjects must not have any active systemic infection requiring ongoing antimicrobial treatment (prophylactic antimicrobial allowed) at time of registration.
• * Subjects must have no known history of HIV, primary immune deficiency disorder, nor be taking a concurrent immune suppressing medication at time of registration. Treatment for CLL/SLL or MM, CLL/SLL related autoimmune phenomenon, or physiologic dosing of corticosteroids (5mg/day prednisone/equivalent or lower) is permitted.